Startups
PTM Therapeutics is focused on developing antibody therapeutics targeting post-translational modifications including glycans. Its primary asset, PTM-001 is being developed for the treatment of Inflammatory Bowel Disease (IBD). Unlike existing IBD therapies PTM-001 does not directly target the immune system but instead, promotes intestinal mucosal wound healing and has demonstrated promising efficacy in in vivo IBD models.
Overview
Location
United States, California, San Mateo
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Biobrit | biobrit.com | |
| MBC BioLabs | mbcbiolabs.com |
Reviews 0
FAQ about PTM Therapeutics, Inc.
Who has invested in PTM Therapeutics, Inc.?
Parsers VC lists 3 investors of PTM Therapeutics, Inc., among them Biobrit and MBC BioLabs.
Is PTM Therapeutics, Inc. still active?
Yes, PTM Therapeutics, Inc. is active; its latest activity on Parsers VC dates from Nov 18, 2020.